Evan David Seigerman, BMO, joins ‘Fast Money’ to talk what Trump appointments mean for the biotech and pharma sectors.
Source link
Trending
- Market optimism levels too high going into 2025, warns Wall Street forecaster Jim Bianco
- Xi says no one can stop China’s ‘reunification’ with Taiwan
- What the incoming cold snap could mean for energy prices
- UBS names 2 renewable stocks with over 55% upside on watch for 2025
- Michelle Caruso Cabrera talks outlook for global markets in 2025
- Best Credit Cards for Medical Expenses of 2025
- Final Trade: COST, MP, STZ
- ‘Santa Claus Rally’ indicator is failing as 2024 ends on sour note
BMO expects Trump to pick a more conventional FDA commissioner after RFK Jr.'s nomination
